While T790M mutation occurs in less than 5% of untreated EGFR mutant lung adenocarcinomas, about 50%–70% of the EGFR mutated tumors develop T790M mutation as an acquired resistance if treated with first-generation TKIs (14). Here, EGFR is linked to lung adenocarcinoma.